Advaxis, Inc. (NASDAQ: ADXS), a clinical stage biotechnology company, focused on Lm-LLO cancer immunotherapies has announced that Anthony Lombardo, interim chief executive officer, will present a company overview at the Cantor Fitzgerald Global Healthcare Conference being held Sept. 25-27, 2017 in New York.
Lombardo has nearly 30 years of leadership experience in the life sciences industry with a proven track record of helping global companies achieve significant growth. Honored by the American College of Radiology and the Society of Abdominal Radiology for his years of service to the clinical community, he currently serves as chairman of the advisory board of Morristown Medical Center, a part of Atlantic Health System Hospitals.
The company’s shares have declined almost 30% after recent quarterly financials indicated a wider loss per share in the YOY period.
Advaxis intends to begin a combination study with Opdivo from Bristol-Myers Squibb that could lead to another application for treatment of cervical cancer, but the study isn’t slated to begin until next year. The company also has another candidate, ADXS-PSA, in early-stage combination therapy trials with Keytruda from Merck & Co. that could lead to a prostate cancer application.
The ADXS immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. Advaxis has four franchises in various stages of clinical and pre-clinical development: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Anavex Life Sciences Corp (NASDAQ: AVXL) was issued U.S. Patent Number 9,750,746 entitled “ANAVEX 2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection. The patent provides the Company with intellectual property protection covering composition of matter for ANAVEX™ 2-73 directed to a novel and synergistic neuroprotective compound combined with donepezil. The issued patent offers protection through 2033.
“This newly issued patent expands the proprietary position of ANAVEX™ 2-73,” said Christopher U. Missling, PhD, President, and Chief Executive Officer of Anavex. “This new patent is a continuation of Anavex’s vigorous pursuit of intellectual property protection for our neuroprotective therapeutics and we look forward to continued progress, including advancing ANAVEX™ 2-73 in clinical studies this year. “
ANAVEX™ 2-73 is an orally available, small-molecule activator of the sigma-1 receptor which, data suggest, is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.1 Donepezil is currently the leading compound for the treatment of Alzheimer’s disease in more than 50 countries and is postulated to exert a therapeutic effect by enhancing cholinergic function. ANAVEX™ 2-73 is to advance this year into a Phase 2/3 clinical trial for the treatment of Alzheimer’s disease, as well as other neurodegenerative and neurodevelopmental CNS indications, including the orphan designation Rett syndrome.
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, today announced that the company will exhibit at the upcoming 2017 BioProcess International Conference & Exhibition, being held September 25-28, 2017 in Boston, MA. Avid will showcase the company’s comprehensive range of process development, analytical development, testing and characterization services and high-quality cGMP clinical and commercial biologics manufacturing of monoclonal antibodies and recombinant proteins.
At BioProcess International, the Avid team will be able to discuss the company’s innovative processes for generating a broad range of biopharmaceutical product types including monoclonal antibodies, highly-glycosylated recombinant proteins, and enzymes, among others. As previously announced, the company will soon be ready to offer new larger scale capacity from the two recently installed 2,000-liter, single-use bioreactors at the Myford facility.
The Myford facility is designed with cutting-edge, single-use equipment to accommodate a fully disposable biomanufacturing process. A wide range of innovative features are incorporated into this new facility including monolithic modular clean rooms, dedicated support utilities for each key processing area, and the industry’s most advanced single-use production systems and flexible solutions. Uni-directional process flows separate personnel and materials and provide assurance that the design meets the most stringent regulatory requirements for commercial biologics API manufacturing.
Avid Bioservices was established as Peregrine’s internal biologics manufacturing and development group, and began formal operations in January 2002. The company has grown from an internal support operation to a full service CDMO that manufactures bulk drug substance for products that are approved and marketed in over 18 countries by leading biopharma companies, including the US and EU. Avid was recently recognized as a leading CDMO by Life Science Leader as a recipient of multiple 2017 Contract Manufacturing Leadership Awards for Quality, Reliability, Capabilities, Expertise, and Compatibility.
22nd Century Group, Inc. (NYSE: XXII) Mitch Zeller, Director, US Food and Drug Administration’s Center for Tobacco Products. Together with FDA Commissioner, Dr. Scott Gottlieb, in August 2017, released an article entitled, “A Nicotine-Focused Framework of Public Health.” The article spells out the FDA’s regulatory authority for mandating non-addictive levels of nicotine in combustible cigarettes.
Dr. Dorothy Hatsukami, Forster Family Chair in Cancer Prevention; Associate Director, Masonic Cancer Center; and Professor of Psychiatry, University of Minnesota. In 2016, together with two other prominent scientists, Dr. Dorothy Hatsukami wrote in Tobacco Control that failure to act on the World Health Organization (WHO) recommendation of mandating nicotine reductions in cigarettes to non-addictive levels could lead to the loss of millions of lives.
“Since the FDA announced its intention to mandate that all cigarettes have very low, non-addictive levels of nicotine, the public health community has focused much of its attention on 22nd Century,” explained Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group. “We look forward to working together with scientists and policymakers to make Very Low Nicotine cigarettes a public health reality in the United States and around the world.”
22nd Century is a plant biotechnology company focused on genetic engineering and plant breeding which allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants.
Free membership limited time below.
See our track record, it speaks for itself…
Traders News Source recent profiles and track record, 380% in verifiable potential gains for our members on 3 small cap alerts alone! These are just three examples from over two dozen winners this year. We have had the #1 gainer on the entire NASDAQ exchange 8 times this year so far and one that was the #1 gainer on the exchange two days in a row (NASDAQ: SPEX) moved from $1.01 to $4.75/ share within three days of our profile.
January 31st, 2017 (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days- http://finance.yahoo.com/news/himax-technologies-review-4q-2016-130000319.html
May 23rd, 2016- (NYSE: XXII) opened at $.87/share hit a high of $3.03/share so far our member potential gains- 248% – http://mailchi.mp/tradersnewssource/updates-5-of-our-profiles-for-212-400-and-whats-coming-next?e=[UNIQID]
(NASDAQ: OBCI) coverage began February 7th, 2017 opening at $4.10/share. This coverage was due to the consistent exceptional quarterly growth coupled with a special divvy issued last year and as anticipated was announced again this year. So far OBCI has traded as high as $5.90/share for potential gains of 43% so far. http://mailchi.mp/tradersnewssource/updates-5-of-our-profiles-for-212-400-and-whats-coming-next?e=[UNIQID]
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
Big Opportunities Trading Small Cap Stocks
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Traders” to the phone number “25827” from your cell phone***
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author, Mark Roberts.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
